Phase 2 study of CT-322, a targeted biologic inhibitor of...

Investigational New Drugs 2015 / 2 Vol. 33; Iss. 1

Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma

Schiff, David, Kesari, Santosh, de Groot, John, Mikkelsen, Tom, Drappatz, Jan, Coyle, Thomas, Fichtel, Lisa, Silver, Bruce, Walters, Ian, Reardon, David
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
33
Language:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-014-0186-2
Date:
February, 2015
File:
PDF, 526 KB
english, 2015
Conversion to is in progress
Conversion to is failed